What is a Patient Information Leaflet and why is it useful?

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

Below is a text only representation of the Patient Information Leaflet, the original can be viewed in PDF format using the link above.

The text only version may be available from RNIB in large print, Braille or audio CD. For further information call RNIB Medicine Leaflet Line on 0800 198 5000. The product code(s) for this leaflet are: EU/1/04/276/029, EU/1/04/276/028, EU/1/04/276/025, EU/1/04/276/026, EU/1/04/276/027, EU/1/04/276/024.

Abilify Orodispersible Tablets

Package leaflet: Information for the user

ABILIFY 10 mg orodispersible tablets

ABILIFY 15 mg orodispersible tablets

ABILIFY 30 mg orodispersible tablets

aripiprazole

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What ABILIFY orodispersible tablets are and what they are used for
2. What you need to know before you take ABILIFY orodispersible tablets
3. How to take ABILIFY orodispersible tablets
4. Possible side effects
5 How to store ABILIFY orodispersible tablets
6. Contents of the pack and other information

1. What ABILIFY orodispersible tablets are and what they are used for

ABILIFY orodispersible tablets contain the active substance aripiprazole and belong to a group of medicines called antipsychotics. It is used to treat adults and adolescents aged 15 years and older who suffer from a disease characterised by symptoms such as hearing, seeing or sensing things which are not there, suspiciousness, mistaken beliefs, incoherent speech and behaviour and emotional flatness. People with this condition may also feel depressed, guilty, anxious or tense.

ABILIFY orodispersible tablets are used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability. In adults it also prevents this condition from returning in patients who have responded to the treatment with ABILIFY orodispersible tablets.

2. What you need to know before you take ABILIFY orodispersible tablets

Do not take ABILIFY orodispersible tablets

  • if you are allergic to aripiprazole or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor before taking ABILIFY orodispersible tablets if you suffer from

  • high blood sugar (characterised by symptoms such as excessive thirst, passing of large amounts of urine, increase in appetite, and feeling weak) or family history of diabetes
  • seizure
  • involuntary, irregular muscle movements, especially in the face
  • cardiovascular diseases, family history of cardiovascular disease, stroke or "mini" stroke, abnormal blood pressure
  • blood clots, or family history of blood clots, as antipsychotics have been associated with formation of blood clots
  • past experience of excessive gambling

If you notice you are gaining weight, develop unusual movements, experience somnolence that interferes with normal daily activities, any difficulty in swallowing or allergic symptoms, please tell your doctor.

If you are an elderly patient suffering from dementia (loss of memory and other mental abilities), you or your carer/relative should tell your doctor if you have ever had a stroke or "mini" stroke.

Tell your doctor immediately if you are having any thoughts or feelings about hurting yourself. Suicidal thoughts and behaviours have been reported during aripiprazole treatment.

Tell your doctor immediately if you suffer from muscle stiffness or inflexibility with high fever, sweating, altered mental status, or very rapid or irregular heart beat.

Children and adolescents

Do not use this medicine in children and adolescents under 13 years of age. It is not known if it is safe and effective in these patients.

Other medicines and ABILIFY orodispersible tablets

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.

Blood pressure-lowering medicines: ABILIFY orodispersible tablets may increase the effect of medicines used to lower the blood pressure. Be sure to tell your doctor if you take a medicine to keep your blood pressure under control.

Taking ABILIFY orodispersible tablets with some medicines may need to change your dose of ABILIFY orodispersible tablets. It is especially important to mention the following to your doctor:

  • Medicines to correct heart rhythm
  • Antidepressants or herbal remedy used to treat depression and anxiety
  • Antifungal agents
  • Certain medicines to treat HIV infection
  • Anticonvulsants used to treat epilepsy

Medicines that increase the level of serotonin: triptans, tramadol, tryptophan, SSRIs (such as paroxetine and fluoxetine), tricyclics (such as clomipramine, amitriptyline), pethidine, St John’s Wort and venlafaxine. These medicines increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with ABILIFY orodispersible tablets, you should see your doctor.

ABILIFY orodispersible tablets with food, drink and alcohol

ABILIFY orodispersible tablets can be taken regardless of meals.

Alcohol should be avoided.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

The following symptoms may occur in newborn babies, of mothers that have used ABILIFY orodispersible tablets in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.

Be sure to tell your doctor immediately if you are breast-feeding.

If you are taking ABILIFY orodispersible tablets, you should not breast-feed.

Driving and using machines

Do not drive or use any tools or machines, until you know how ABILIFY orodispersible tablets affect you.

ABILIFY orodispersible tablets contain aspartame

Patients who cannot take phenylalanine should note that ABILIFY orodispersible tablets contain aspartame, which is a source of phenylalanine. May be harmful for people with phenylketonuria.

ABILIFY orodispersible tablets contain lactose

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

3. How to take ABILIFY orodispersible tablets

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose for adults is 15 mg once a day. However your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day.

Use in children and adolescents

This medicinal product may be started at a low dose with the oral solution (liquid) form.

The dose may be gradually increased to the recommended dose for adolescents of 10 mg once a day. However your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day.

If you have the impression that the effects of your ABILIFY orodispersible tablets are too strong or too weak, talk to your doctor or pharmacist.

Try to take your ABILIFY orodispersible tablets at the same time each day. It does not matter whether you take it with or without food.

Do not open the blister until ready to administer. For single tablet removal, open the package and peel back the foil on the blister to expose the tablet. Do not push the tablet through the foil because this could damage the tablet. Immediately upon opening the blister, using dry hands, remove the tablet and place the entire orodispersible tablet on the tongue. Tablet disintegration occurs rapidly in saliva. The orodispersible tablet can be taken with or without liquid.

Alternatively, disperse the tablet in water and drink the resulting suspension.

Even if you feel better, do not alter or discontinue the daily dose of ABILIFY orodispersible tablets without first consulting your doctor.

If you take more ABILIFY orodispersible tablets than you should

If you realise you have taken more ABILIFY orodispersible tablets than your doctor has recommended (or if someone else has taken some of your ABILIFY orodispersible tablets), contact your doctor right away. If you cannot reach your doctor, go to the nearest hospital and take the pack with you.

If you forget to take ABILIFY orodispersible tablets

If you miss a dose, take the missed dose as soon as you remember but do not take two doses in one day.

If you stop taking ABILIFY orodispersible tablets

Do not stop your treatment just because you feel better. It is important that you carry on taking ABILIFY orodispersible tablets for as long as your doctor has told you to.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Common side effects (may affect up to 1 in 10 people):

  • diabetes mellitus,
  • difficulty sleeping,
  • feeling anxious,
  • feeling restless and unable to keep still, difficulty sitting still,
  • uncontrollable twitching, jerking or writhing movements, restless legs,
  • trembling,
  • headache,
  • tiredness,
  • sleepiness,
  • light-headedness,
  • shaking and blurred vision,
  • decreased number of or difficulty making bowel movements,
  • indigestion,
  • feeling sick,
  • more saliva in mouth than normal,
  • vomiting,
  • feeling tired.

Uncommon side effects (may affect up to 1 in 100 people):

  • increased blood levels of the hormone prolactin,
  • too much sugar in the blood,
  • depression,
  • altered or increased sexual interest,
  • uncontrollable movements of mouth, tongue and limbs (tardive dyskinesia),
  • muscle disorder causing twisting movements (dystonia),
  • double vision,
  • fast heart beat,
  • a fall in blood pressure on standing up which causes dizziness, light-headedness or fainting,
  • hiccups.

The following side effects have been reported since the marketing of oral aripiprazole but the frequency for them to occur is not known:

  • low levels of white blood cells,
  • low levels of blood platelets,
  • allergic reaction (e.g. swelling in the mouth, tongue, face and throat, itching, hives),
  • onset or worsening of diabetes, ketoacidosis (ketones in the blood and urine) or coma,
  • high blood sugar,
  • not enough sodium in the blood,
  • loss of appetite (anorexia),
  • weight loss,
  • weight gain,
  • thoughts of suicide, suicide attempt and suicide,
  • excessive gambling,
  • feeling aggressive,
  • agitation,
  • nervousness,
  • combination of fever, muscle stiffness, faster breathing, sweating, reduced consciousness and sudden changes in blood pressure and heart rate, fainting (neuroleptic malignant syndrome),
  • seizure,
  • serotonin syndrome (a reaction which may cause feelings of great happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid muscles),
  • speech disorder,
  • sudden unexplained death,
  • life-threatening irregular heart beat,
  • heart attack,
  • slower heart beat,
  • blood clots in the veins especially in the legs (symptoms include swelling, pain and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing (if you notice any of these symptoms, seek medical advice immediately),
  • high blood pressure,
  • fainting,
  • accidental inhalation of food with risk of pneumonia (lung infection),
  • spasm of the muscles around the voice box,
  • inflammation of the pancreas,
  • difficulty swallowing,
  • diarrhoea,
  • abdominal discomfort,
  • stomach discomfort,
  • liver failure,
  • inflammation of the liver,
  • yellowing of the skin and white part of eyes,
  • reports of abnormal liver tests values,
  • skin rash,
  • sensitivity to light,
  • baldness,
  • excessive sweating,
  • abnormal muscle breakdown which can lead to kidney problems,
  • muscle pain,
  • stiffness,
  • involuntary loss of urine (incontinence),
  • difficulty in passing urine,
  • withdrawal symptoms in newborn babies in case of exposure during pregnancy,
  • prolonged and/or painful erection,
  • difficulty controlling core body temperature or overheating,
  • chest pain,
  • swelling of hands, ankles or feet,
  • in blood tests: fluctuating blood sugar, increased glycosylated haemoglobin.

In elderly patients with dementia, more fatal cases have been reported while taking aripiprazole. In addition, cases of stroke or "mini" stroke have been reported.

Additional side effects in children and adolescents

Adolescents aged 13 years and older experienced side effects that were similar in frequency and type to those in adults except that sleepiness, uncontrollable twitching or jerking movements, restlessness, and tiredness were very common (greater than 1 in 10 patients) and upper abdominal pain, dry mouth, increased heart rate, weight gain, increased appetite, muscle twitching, uncontrolled movements of the limbs, and feeling dizzy, especially when getting up from a lying or sitting position, were common (greater than 1 in 100 patients).

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store ABILIFY orodispersible tablets

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the blister and on the carton after EXP. The expiry date refers to the last day of that month.

Store in the original package in order to protect from moisture.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What ABILIFY orodispersible tablets contain

  • The active substance is aripiprazole.
    Each orodispersible tablet contains 10 mg of aripiprazole.
    Each orodispersible tablet contains 15 mg of aripiprazole.
    Each orodispersible tablet contains 30 mg of aripiprazole.
  • The other ingredients are calcium silicate, croscarmellose sodium, crospovidone, silicon dioxide, xylitol, microcrystalline cellulose, aspartame, acesulfame potassium, vanilla flavour, tartaric acid and magnesium stearate.
    Tablet coat
    ABILIFY 10 mg orodispersible tablets: Red iron oxide (E 172)
    ABILIFY 15 mg orodispersible tablets: Yellow iron oxide (E 172)
    ABILIFY 30 mg orodispersible tablets: Red iron oxide (E 172)

What ABILIFY orodispersible tablets looks like and contents of the pack

ABILIFY 10 mg orodispersible tablets are round and pink, marked with ‘"A" over "640"’ on one side and ‘10’ on the other.

ABILIFY 15 mg orodispersible tablets are round and yellow, marked with ‘"A" over "641"’ on one side and ‘15’ on the other.

ABILIFY 30 mg orodispersible tablets are round and pink, marked with ‘"A" over "643"’ on one side and ‘30’ on the other.

ABILIFY orodispersible tablets are supplied in perforated unit dose blisters packed in cartons containing 14 x 1, 28 x 1, or 49 x 1 orodispersible tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Otsuka Pharmaceutical Europe Ltd.
Gallions
Wexham Springs
Framewood Road
Wexham
SL3 6PJ
United Kingdom

Manufacturer

Bristol-Myers Squibb S.r.l.
Contrada Fontana del Ceraso
I-03012 Anagni-Frosinone
Italy

Elaiapharm
2881 Route des Crêtes
Z.I. Les Bouilides-Sophia Antipolis
06560 Valbonne
France

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

United Kingdom
Otsuka Pharmaceuticals (UK) Ltd.
Tel: +44 (0)203 747 5300

This leaflet was last revised in 09/2016

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.